Literature DB >> 27053449

Bladder dose-surface maps and urinary toxicity: Robustness with respect to motion in assessing local dose effects.

F Palorini1, A Botti2, V Carillo3, S Gianolini4, I Improta3, C Iotti5, T Rancati6, C Cozzarini7, C Fiorino3.   

Abstract

The purpose of this study was to quantify the impact of inter-fraction modifications of bladder during RT of prostate cancer on bladder dose surface maps (DSM). Eighteen patients treated with daily image-guided Tomotherapy and moderate hypofractionation (70-72.8Gy at 2.5-2.6Gy/fr in 28 fractions and full bladder) were considered. Bladder contours were delineated on co-registered daily Megavoltage CT (MVCT) by a single observer and copied on the planning CT to generate dose-volume/surface histograms (DVH/DSH) and bladder DSMs. Discrepancies between planned and daily absorbed doses were analyzed through the average of individual systematic errors, the population systematic errors and the population random errors for the DVH/DSHs and DSMs. In total, 477 DVH/DSH and 472 DSM were available. DSH and DVH showed small population systematic errors of absolute surfaces (<3.4cm(2)) and volumes (<8.4cm(3)) at the highest doses. The dose to the posterior bladder base assessed on DSMs showed a mean systematic error below 1Gy, with population systematic and random errors within 4 and 3Gy, respectively. The region surrounding this area shows higher mean systematic errors (1-3Gy), population systematic (8-11Gy) and random (5-7Gy) errors. In conclusion, DVH/DSH and DSMs are quite stable with respect to inter-fraction variations in the high-dose region, within about 2cm from bladder base. Larger systematic variations occur in the anterior portion and cranially 2.5-3.5cm from the base. Results suggest that dose predictors related to the high dose area (including the trigone dose) are likely to be sufficiently reliable with respect to the expected variations due to variable bladder filling.
Copyright © 2016 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bladder; Dose–surface maps; Inter-fraction motion

Mesh:

Year:  2016        PMID: 27053449     DOI: 10.1016/j.ejmp.2016.03.006

Source DB:  PubMed          Journal:  Phys Med        ISSN: 1120-1797            Impact factor:   2.685


  6 in total

1.  Bladder surface dose modeling in prostate cancer radiotherapy: An analysis of motion-induced variations and the cumulative dose across the treatment.

Authors:  Yi Lao; Minsong Cao; Yingli Yang; Amar U Kishan; Wensha Yang; Yalin Wang; Ke Sheng
Journal:  Med Phys       Date:  2021-11-16       Impact factor: 4.071

2.  Delivered dose can be a better predictor of rectal toxicity than planned dose in prostate radiotherapy.

Authors:  L E A Shelley; J E Scaife; M Romanchikova; K Harrison; J R Forman; A M Bates; D J Noble; R Jena; M A Parker; M P F Sutcliffe; S J Thomas; N G Burnet
Journal:  Radiother Oncol       Date:  2017-04-28       Impact factor: 6.280

3.  Dose surface maps of the heart can identify regions associated with worse survival for lung cancer patients treated with radiotherapy.

Authors:  Alan McWilliam; Chloe Dootson; Lewis Graham; Kathryn Banfill; Azadeh Abravan; Marcel van Herk
Journal:  Phys Imaging Radiat Oncol       Date:  2020-07-30

4.  A case-control study using motion-inclusive spatial dose-volume metrics to account for genito-urinary toxicity following high-precision radiotherapy for prostate cancer.

Authors:  Oscar Casares-Magaz; Ludvig P Muren; Niclas Pettersson; Maria Thor; Austin Hopper; Rick Knopp; Joseph O Deasy; Michael Væth; John Einck; Vitali Moiseenko
Journal:  Phys Imaging Radiat Oncol       Date:  2018-10-05

5.  Towards spatial representations of dose distributions to predict risk of normal tissue morbidity after radiotherapy.

Authors:  Oscar Casares-Magaz; Vitali Moiseenko; Marnix Witte; Tiziana Rancati; Ludvig P Muren
Journal:  Phys Imaging Radiat Oncol       Date:  2020-08-28

6.  Development of a prediction model for late urinary incontinence, hematuria, pain and voiding frequency among irradiated prostate cancer patients.

Authors:  Wouter Schaake; Arjen van der Schaaf; Lisanne V van Dijk; Alfons C M van den Bergh; Johannes A Langendijk
Journal:  PLoS One       Date:  2018-07-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.